D-0280-2019 Class II Terminated
FDA drug recall D-0280-2019 was initiated by Upsher Smith Laboratories, Inc. on Sep 19, 2018 and is designated Class II. Reason for recall: Failed impurities/ degradation specifications: Product is Out of Specification for an unspecified degradation product. The recall status is terminated (terminated Sep 30, 2020). Affected quantity: 44,764 bottles.
Recall details
- Product Type
- Drugs
- Report Date
- Oct 31, 2018
- Initiation Date
- Sep 19, 2018
- Termination Date
- Sep 30, 2020
- Voluntary/Mandated
- Voluntary: Firm initiated
- Product Quantity
- 44,764 bottles
Product description
Bumetanide Tablets, USP, 1 mg, 100-count bottle, Rx only, Manufactured by: Upser-Smith Laboratories, LLC, Maple Grove, MN 55369, NDC 0832-0541-11
Reason for recall
Failed impurities/ degradation specifications: Product is Out of Specification for an unspecified degradation product.
Distribution pattern
Nationwide USA, Puerto Rico and Guam
Code information
Lot#: 375716, Exp 4/30/2020; 372957, 372958, 372959, Exp 3/31/2020; 374541, 375717, 376688, Exp 5/31/2020
Source
- Dataset
- openFDA drug recall enforcement reports
- FDA record
- This recall in openFDA (JSON)
- Enforcement Report
- Search FDA's Enforcement Report for D-0280-2019
- openFDA file date
- Nov 16, 2026
- Loaded by RegDataLab
- Nov 17, 2026